AlphaGenome, accessible via API, cracks the “junk DNA” code, outperforms top rivals in key tests, and puts advanced genomics tools within reach of labs around the world.
The analysts set a price target of $510, writing that the share price could also benefit from the company's varied initiatives and dominant market position.